OCUL vs. INVA, PLRX, ARQT, PHAT, KNSA, AXSM, MRUS, RARE, INSM, and HCM
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Innoviva (INVA), Pliant Therapeutics (PLRX), Arcutis Biotherapeutics (ARQT), Phathom Pharmaceuticals (PHAT), Kiniksa Pharmaceuticals (KNSA), Axsome Therapeutics (AXSM), Merus (MRUS), Ultragenyx Pharmaceutical (RARE), Insmed (INSM), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical preparations" industry.
Ocular Therapeutix (NASDAQ:OCUL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.
Innoviva has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
In the previous week, Innoviva had 2 more articles in the media than Ocular Therapeutix. MarketBeat recorded 5 mentions for Innoviva and 3 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 1.89 beat Innoviva's score of 1.74 indicating that Ocular Therapeutix is being referred to more favorably in the media.
59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 5.5% of Ocular Therapeutix shares are owned by insiders. Comparatively, 1.4% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Ocular Therapeutix presently has a consensus target price of $15.17, suggesting a potential upside of 161.95%. Given Ocular Therapeutix's higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Innoviva.
Ocular Therapeutix received 131 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 69.72% of users gave Ocular Therapeutix an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
Innoviva has a net margin of 58.21% compared to Ocular Therapeutix's net margin of -192.61%. Innoviva's return on equity of 28.94% beat Ocular Therapeutix's return on equity.
Ocular Therapeutix has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.
Summary
Innoviva beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
